Torrance Clinical Research Institute, Inc. | Lomita, CA

Research site

(Unclaimed)

Location

25043 Narbonne Avenue, Lomita, California, United States of America

Site insights

Top conditions

Top treatments

Relamorelin

Amlitelimab

Vonoprazan

EDP-938

Triglyceride

Atogepant

K-877

AVP-786

Aducanumab

Lansoprazole

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 57 total trials

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to p...

Begins enrollment in 1 month

Diabetes Mellitus, Type 2

Drug: Semaglutide

Drug: NNC0662-0419

A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

The purpose of this study is to assess the efficacy and safety of verekitug (UPB-101) in participants with moderate-to-severe Chronic Obstructive Pul...

Enrolling

Chronic Obstructive Pulmonary Disease

Other: Placebo

Drug: Verekitug

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm monotherapy study for treatment of...

Active, not recruiting

Dermatitis Atopic

Drug: Placebo

Drug: Amlitelimab

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (ESTUARY)

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 yea...

Active, not recruiting

Dermatitis Atopic

Drug: Placebo

Drug: Amlitelimab

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease (PREVAIL)

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Obicetrapib

Drug: Placebo

Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects (APOLLOE4-LTE)

This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 ge...

Active, not recruiting

Early Alzheimer's Disease

Drug: Experimental: ALZ-801

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials (RIVER-AD)

This is an open-label, Phase 2/Phase 3, long-term extension study for treatment of participants of previous amlitelimab clinical trials in moderate t...

Invitation-only

Dermatitis Atopic

Drug: Topical calcineurin inhibitors

Drug: Topical corticosteroids